世界の臨床腫瘍学次世代シーケンシング（NGS）市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Clinical Oncology Next Generation Sequencing (NGS) Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z1374
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、134ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、臨床腫瘍学次世代シーケンシング（NGS）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（NGSプレシーケンシング、シーケンシング、NGSデータ分析、一次、二次、三次データ分析）、用途別市場規模（学術・臨床研究、病院・クリニック、製薬・バイオテクノロジー事業体）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・臨床腫瘍学次世代シーケンシング（NGS）の市場動向
・企業の競争状況、市場シェア
・臨床腫瘍学次世代シーケンシング（NGS）の種類別市場規模（NGSプレシーケンシング、シーケンシング、NGSデータ分析、一次、二次、三次データ分析）
・臨床腫瘍学次世代シーケンシング（NGS）の用途別市場規模（学術・臨床研究、病院・クリニック、製薬・バイオテクノロジー事業体）
・臨床腫瘍学次世代シーケンシング（NGS）の北米市場規模2016-2027（アメリカ、カナダ）
・臨床腫瘍学次世代シーケンシング（NGS）のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・臨床腫瘍学次世代シーケンシング（NGS）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・臨床腫瘍学次世代シーケンシング（NGS）の中南米市場規模2016-2027（メキシコ、ブラジル）
・臨床腫瘍学次世代シーケンシング（NGS）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Illumina、Roche、Agilent Technologies、Knome、Genomatix Software、GATC Biotech、Oxford Nanopore Technologies、Macrogen、Life Technologies、DNASTAR、Exosome Diagnostics、Biomatters、CLC Bio、BGI、Qiagen、Perkin Elmer、Pacific Bioscience、Partek、GnuBIO、Foundation Medicine、Paradigm、Caris Life Sciences、Myriad Genetics）
・結論

NGS allows the testing of all types of variants including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes and translocations.
The key factor contributing to the growth of the NGS market is the improved understanding of the genetic markers of virulence and resistance.

Market Analysis and Insights: Global Clinical Oncology Next Generation Sequencing (NGS) Market
The global Clinical Oncology Next Generation Sequencing (NGS) market size is projected to reach US$ 1429.7 million by 2026, from US$ 704.7 million in 2019, at a CAGR of 10.6% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Clinical Oncology Next Generation Sequencing (NGS) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Clinical Oncology Next Generation Sequencing (NGS) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Clinical Oncology Next Generation Sequencing (NGS) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Clinical Oncology Next Generation Sequencing (NGS) market.

Global Clinical Oncology Next Generation Sequencing (NGS) Scope and Market Size
Clinical Oncology Next Generation Sequencing (NGS) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Clinical Oncology Next Generation Sequencing (NGS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
NGS Pre-Sequencing
Sequencing
NGS Data Analysis
Primary, Secondary & Tertiary Data Analysis

Segment by Application
Academic & Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
Knome
Genomatix Software
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 NGS Pre-Sequencing
1.2.3 Sequencing
1.2.4 NGS Data Analysis
1.2.5 Primary, Secondary & Tertiary Data Analysis
1.3 Market by Application
1.3.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Academic & Clinical Research
1.3.3 Hospitals & Clinics
1.3.4 Pharma & Biotech Entities
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Perspective (2016-2027)
2.2 Clinical Oncology Next Generation Sequencing (NGS) Growth Trends by Regions
2.2.1 Clinical Oncology Next Generation Sequencing (NGS) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Clinical Oncology Next Generation Sequencing (NGS) Historic Market Share by Regions (2016-2021)
2.2.3 Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Regions (2022-2027)
2.3 Clinical Oncology Next Generation Sequencing (NGS) Industry Dynamic
2.3.1 Clinical Oncology Next Generation Sequencing (NGS) Market Trends
2.3.2 Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
2.3.3 Clinical Oncology Next Generation Sequencing (NGS) Market Challenges
2.3.4 Clinical Oncology Next Generation Sequencing (NGS) Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue
3.1.1 Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Revenue (2016-2021)
3.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Players (2016-2021)
3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Clinical Oncology Next Generation Sequencing (NGS) Revenue
3.4 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio
3.4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2020
3.5 Clinical Oncology Next Generation Sequencing (NGS) Key Players Head office and Area Served
3.6 Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
3.7 Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Clinical Oncology Next Generation Sequencing (NGS) Breakdown Data by Type
4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Type (2016-2021)
4.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2022-2027)

5 Clinical Oncology Next Generation Sequencing (NGS) Breakdown Data by Application
5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Historic Market Size by Application (2016-2021)
5.2 Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2016-2027)
6.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
6.2.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2021)
6.2.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2022-2027)
6.2.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2027)
6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application
6.3.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2021)
6.3.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2022-2027)
6.3.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2027)
6.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
6.4.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2016-2021)
6.4.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (2016-2027)
7.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
7.2.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2021)
7.2.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2022-2027)
7.2.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2027)
7.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application
7.3.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2021)
7.3.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2022-2027)
7.3.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2027)
7.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
7.4.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2016-2021)
7.4.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size (2016-2027)
8.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
8.2.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2027)
8.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application
8.3.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2027)
8.4 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region
8.4.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2016-2027)
9.2 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
9.2.1 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2021)
9.2.2 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2022-2027)
9.2.3 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2027)
9.3 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application
9.3.1 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2021)
9.3.2 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2022-2027)
9.3.3 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2027)
9.4 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
9.4.1 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2016-2021)
9.4.2 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size (2016-2027)
10.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
10.2.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2027)
10.3 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application
10.3.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2027)
10.4 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
10.4.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Illumina
11.1.1 Illumina Company Details
11.1.2 Illumina Business Overview
11.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.1.4 Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.1.5 Illumina Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.2.4 Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.2.5 Roche Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Details
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.3.4 Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.3.5 Agilent Technologies Recent Development
11.4 Knome
11.4.1 Knome Company Details
11.4.2 Knome Business Overview
11.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.4.4 Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.4.5 Knome Recent Development
11.5 Genomatix Software
11.5.1 Genomatix Software Company Details
11.5.2 Genomatix Software Business Overview
11.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.5.4 Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.5.5 Genomatix Software Recent Development
11.6 GATC Biotech
11.6.1 GATC Biotech Company Details
11.6.2 GATC Biotech Business Overview
11.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.6.4 GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.6.5 GATC Biotech Recent Development
11.7 Oxford Nanopore Technologies
11.7.1 Oxford Nanopore Technologies Company Details
11.7.2 Oxford Nanopore Technologies Business Overview
11.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.7.4 Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.7.5 Oxford Nanopore Technologies Recent Development
11.8 Macrogen
11.8.1 Macrogen Company Details
11.8.2 Macrogen Business Overview
11.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.8.4 Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.8.5 Macrogen Recent Development
11.9 Life Technologies
11.9.1 Life Technologies Company Details
11.9.2 Life Technologies Business Overview
11.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.9.4 Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.9.5 Life Technologies Recent Development
11.10 DNASTAR
11.10.1 DNASTAR Company Details
11.10.2 DNASTAR Business Overview
11.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.10.4 DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.10.5 DNASTAR Recent Development
11.11 Exosome Diagnostics
11.11.1 Exosome Diagnostics Company Details
11.11.2 Exosome Diagnostics Business Overview
11.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.11.4 Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.11.5 Exosome Diagnostics Recent Development
11.12 Biomatters
11.12.1 Biomatters Company Details
11.12.2 Biomatters Business Overview
11.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.12.4 Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.12.5 Biomatters Recent Development
11.13 CLC Bio
11.13.1 CLC Bio Company Details
11.13.2 CLC Bio Business Overview
11.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.13.4 CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.13.5 CLC Bio Recent Development
11.14 BGI
11.14.1 BGI Company Details
11.14.2 BGI Business Overview
11.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.14.4 BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.14.5 BGI Recent Development
11.15 Qiagen
11.15.1 Qiagen Company Details
11.15.2 Qiagen Business Overview
11.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.15.4 Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.15.5 Qiagen Recent Development
11.16 Perkin Elmer
11.16.1 Perkin Elmer Company Details
11.16.2 Perkin Elmer Business Overview
11.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.16.4 Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.16.5 Perkin Elmer Recent Development
11.17 Pacific Bioscience
11.17.1 Pacific Bioscience Company Details
11.17.2 Pacific Bioscience Business Overview
11.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.17.4 Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.17.5 Pacific Bioscience Recent Development
11.18 Partek
11.18.1 Partek Company Details
11.18.2 Partek Business Overview
11.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.18.4 Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.18.5 Partek Recent Development
11.18 GnuBIO
.1 GnuBIO Company Details
.2 GnuBIO Business Overview
.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Introduction
.4 GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
.5 GnuBIO Recent Development
11.20 Foundation Medicine
11.20.1 Foundation Medicine Company Details
11.20.2 Foundation Medicine Business Overview
11.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.20.4 Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.20.5 Foundation Medicine Recent Development
11.21 Paradigm
11.21.1 Paradigm Company Details
11.21.2 Paradigm Business Overview
11.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.21.4 Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.21.5 Paradigm Recent Development
11.22 Caris Life Sciences
11.22.1 Caris Life Sciences Company Details
11.22.2 Caris Life Sciences Business Overview
11.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.22.4 Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.22.5 Caris Life Sciences Recent Development
11.23 Myriad Genetics
11.23.1 Myriad Genetics Company Details
11.23.2 Myriad Genetics Business Overview
11.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Introduction
11.23.4 Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
11.23.5 Myriad Genetics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of NGS Pre-Sequencing
Table 3. Key Players of Sequencing
Table 4. Key Players of NGS Data Analysis
Table 5. Key Players of Primary, Secondary & Tertiary Data Analysis
Table 6. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Regions (2016-2021)
Table 10. Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Regions (2022-2027)
Table 12. Clinical Oncology Next Generation Sequencing (NGS) Market Trends
Table 13. Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
Table 14. Clinical Oncology Next Generation Sequencing (NGS) Market Challenges
Table 15. Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
Table 16. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Players (2016-2021)
Table 18. Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Clinical Oncology Next Generation Sequencing (NGS) as of 2020)
Table 19. Ranking of Global Top Clinical Oncology Next Generation Sequencing (NGS) Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Clinical Oncology Next Generation Sequencing (NGS) Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Clinical Oncology Next Generation Sequencing (NGS) Product Solution and Service
Table 23. Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type (2016-2021)
Table 27. Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Application (2016-2021)
Table 31. Global Clinical Oncology Next Generation Sequencing (NGS) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (2022-2027) & (US$ Million)
Table 63. Illumina Company Details
Table 64. Illumina Business Overview
Table 65. Illumina Clinical Oncology Next Generation Sequencing (NGS) Product
Table 66. Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 67. Illumina Recent Development
Table 68. Roche Company Details
Table 69. Roche Business Overview
Table 70. Roche Clinical Oncology Next Generation Sequencing (NGS) Product
Table 71. Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 72. Roche Recent Development
Table 73. Agilent Technologies Company Details
Table 74. Agilent Technologies Business Overview
Table 75. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product
Table 76. Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 77. Agilent Technologies Recent Development
Table 78. Knome Company Details
Table 79. Knome Business Overview
Table 80. Knome Clinical Oncology Next Generation Sequencing (NGS) Product
Table 81. Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 82. Knome Recent Development
Table 83. Genomatix Software Company Details
Table 84. Genomatix Software Business Overview
Table 85. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product
Table 86. Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 87. Genomatix Software Recent Development
Table 88. GATC Biotech Company Details
Table 89. GATC Biotech Business Overview
Table 90. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product
Table 91. GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 92. GATC Biotech Recent Development
Table 93. Oxford Nanopore Technologies Company Details
Table 94. Oxford Nanopore Technologies Business Overview
Table 95. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product
Table 96. Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 97. Oxford Nanopore Technologies Recent Development
Table 98. Macrogen Company Details
Table 99. Macrogen Business Overview
Table 100. Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 101. Macrogen Recent Development
Table 102. Life Technologies Company Details
Table 103. Life Technologies Business Overview
Table 104. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product
Table 105. Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 106. Life Technologies Recent Development
Table 107. DNASTAR Company Details
Table 108. DNASTAR Business Overview
Table 109. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product
Table 110. DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 111. DNASTAR Recent Development
Table 112. Exosome Diagnostics Company Details
Table 113. Exosome Diagnostics Business Overview
Table 114. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product
Table 115. Exosome Diagnostics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 116. Exosome Diagnostics Recent Development
Table 117. Biomatters Company Details
Table 118. Biomatters Business Overview
Table 119. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product
Table 120. Biomatters Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 121. Biomatters Recent Development
Table 122. CLC Bio Company Details
Table 123. CLC Bio Business Overview
Table 124. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product
Table 125. CLC Bio Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 126. CLC Bio Recent Development
Table 127. BGI Company Details
Table 128. BGI Business Overview
Table 129. BGI Clinical Oncology Next Generation Sequencing (NGS) Product
Table 130. BGI Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 131. BGI Recent Development
Table 132. Qiagen Company Details
Table 133. Qiagen Business Overview
Table 134. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product
Table 135. Qiagen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 136. Qiagen Recent Development
Table 137. Perkin Elmer Company Details
Table 138. Perkin Elmer Business Overview
Table 139. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product
Table 140. Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 141. Perkin Elmer Recent Development
Table 142. Pacific Bioscience Company Details
Table 143. Pacific Bioscience Business Overview
Table 144. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product
Table 145. Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 146. Pacific Bioscience Recent Development
Table 147. Partek Company Details
Table 148. Partek Business Overview
Table 149. Partek Clinical Oncology Next Generation Sequencing (NGS) Product
Table 150. Partek Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 151. Partek Recent Development
Table 152. GnuBIO Company Details
Table 153. GnuBIO Business Overview
Table 154. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product
Table 155. GnuBIO Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 156. GnuBIO Recent Development
Table 157. Foundation Medicine Company Details
Table 158. Foundation Medicine Business Overview
Table 159. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product
Table 160. Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 161. Foundation Medicine Recent Development
Table 162. Paradigm Company Details
Table 163. Paradigm Business Overview
Table 164. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product
Table 165. Paradigm Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 166. Paradigm Recent Development
Table 167. Caris Life Sciences Company Details
Table 168. Caris Life Sciences Business Overview
Table 169. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product
Table 170. Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 171. Caris Life Sciences Recent Development
Table 172. Myriad Genetics Company Details
Table 173. Myriad Genetics Business Overview
Table 174. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product
Table 175. Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021) & (US$ Million)
Table 176. Myriad Genetics Recent Development
Table 177. Research Programs/Design for This Report
Table 178. Key Data Information from Secondary Sources
Table 179. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type: 2020 VS 2027
Figure 2. NGS Pre-Sequencing Features
Figure 3. Sequencing Features
Figure 4. NGS Data Analysis Features
Figure 5. Primary, Secondary & Tertiary Data Analysis Features
Figure 6. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application: 2020 VS 2027
Figure 7. Academic & Clinical Research Case Studies
Figure 8. Hospitals & Clinics Case Studies
Figure 9. Pharma & Biotech Entities Case Studies
Figure 10. Clinical Oncology Next Generation Sequencing (NGS) Report Years Considered
Figure 11. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Regions: 2020 VS 2027
Figure 14. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Regions (2022-2027)
Figure 15. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Players in 2020
Figure 16. Global Top Clinical Oncology Next Generation Sequencing (NGS) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Clinical Oncology Next Generation Sequencing (NGS) as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2020
Figure 18. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type (2016-2021)
Figure 19. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type (2022-2027)
Figure 20. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2016-2027)
Figure 22. North America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2016-2027)
Figure 23. North America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Country (2016-2027)
Figure 24. United States Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2016-2027)
Figure 28. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2016-2027)
Figure 29. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Share by Country (2016-2027)
Figure 30. Germany Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Share by Region (2016-2027)
Figure 40. China Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2016-2027)
Figure 48. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2016-2027)
Figure 49. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Share by Country (2016-2027)
Figure 50. Mexico Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Share by Country (2016-2027)
Figure 56. Turkey Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Clinical Oncology Next Generation Sequencing (NGS) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Illumina Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 60. Roche Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 61. Agilent Technologies Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 62. Knome Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 63. Genomatix Software Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 64. GATC Biotech Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 65. Oxford Nanopore Technologies Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 66. Macrogen Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 67. Life Technologies Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 68. DNASTAR Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 69. Exosome Diagnostics Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 70. Biomatters Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 71. CLC Bio Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 72. BGI Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 73. Qiagen Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 74. Perkin Elmer Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 75. Pacific Bioscience Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 76. Partek Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 77. GnuBIO Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 78. Foundation Medicine Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 79. Paradigm Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 80. Caris Life Sciences Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 81. Myriad Genetics Revenue Growth Rate in Clinical Oncology Next Generation Sequencing (NGS) Business (2016-2021)
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed

Global Next Generation Sequencing (NGS) Market Size, Status and Forecast 2021-2027
QYR2104Z4131 2021年4月 127Pages
QYResearch社発行の本調査資料では、次世代シーケンシング（NGS）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（消耗品、プラットフォーム、サービス）、用途別市場規模（学術＆政府研究機関、製薬会社、バイオテクノロジー会社、病院＆クリニッ...

世界の次世代シーケンシング（NGS）市場規模・現状・予測（2021年-2027年）

世界の第3世代シーケンス市場規模・現状・予測（2021年-2027年）

Global Third-Generation Sequencing Market Size, Status and Forecast 2021-2027
QYR2104Z5633 2021年4月 95Pages
QYResearch社発行の本調査資料では、第3世代シーケンスのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（単一分子リアルタイム（SMRT）DNAシーケンス、ナノポアベース型単一分子分析技術、その他）、用途別市場規模（腫瘍学、遺伝性疾患検出、...

世界の次世代シーケンシング市場規模・現状・予測（2021年-2027年）

Global Next-Generation Sequencing Market Size, Status and Forecast 2021-2027
QYR2104Z4141 2021年4月 97Pages
QYResearch社発行の本調査資料では、次世代シーケンシングのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ターゲットシーケンシング＆リシーケンシング、全ゲノムシーケンシング、全エクソームシーケンシング）、用途別市場規模（腫瘍、遺伝性疾患検...

世界のハイスループットシーケンシング（HTS）市場規模・現状・予測（2021年-2027年）

Global High-Throughput Sequencing (HTS) Market Size, Status and Forecast 2021-2027
QYR2104Z2845 2021年4月 93Pages
QYResearch社発行の本調査資料では、ハイスループットシーケンシング（HTS）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（合成シーケンシング、連結シーケンシング）、用途別市場規模（腫瘍、遺伝性疾患検出、生命科学）、主要地域別市場規模（...

世界のハイスループットシーケンシング（HTS）市場規模・現状・予測（2021年-2027年）

世界の次世代シーケンシング（NGS）データ分析市場規模・現状・予測（2021年-2027年）

Global Next Generation Sequencing (NGS) Data Analysis Market Size, Status and Forecast 2021-2027
QYR2104Z4130 2021年4月 90Pages
QYResearch社発行の本調査資料では、次世代シーケンシング（NGS）データ分析のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（合成別シーケンシング（SBS）技術、単一分子リアルタイムシーケンシング（SMRT）技術、イオン半導体シーケンシン...

世界の次世代シーケンシング情報市場規模・現状・予測（2021年-2027年）

Global Next-Generation Sequencing Informatics Market Size, Status and Forecast 2021-2027
QYR2104Z4140 2021年4月 92Pages
QYResearch社発行の本調査資料では、次世代シーケンシング情報のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（NGS情報サービス、データ分析＆管理ツール、一次＆二次データ分析ツール）、用途別市場規模（病院・診療所、学術研究機関、製薬会社、...

世界のヒトマイクロバイオームシーケンシング技術市場規模・現状・予測（2021年-2027年）

Global Human Microbiome Sequencing Technology Market Size, Status and Forecast 2021-2027
QYR2104Z2954 2021年4月 127Pages
QYResearch社発行の本調査資料では、ヒトマイクロバイオームシーケンシング技術のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（従来型シーケンシング技術、次世代シーケンシング、第3世代シーケンシング）、用途別市場規模（研究・学術機関、製薬・...

世界の新型コロナウイルス感染症独立臨床検査室（ICL）市場規模・現状・予測（2021年-2027年）

Global COVID-19 Independent Clinical Laboratory (ICL) Market Size, Status and Forecast 2021-2027
QYR2104Z1621 2021年4月 92Pages
QYResearch社発行の本調査資料では、新型コロナウイルス感染症独立臨床検査室（ICL）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（総合検査、特別検査）、用途別市場規模（個人、企業、医療機関、その他）、主要地域別市場規模（北米、アメリカ...

世界の第3世代シーケンス市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Third-Generation Sequencing Market The global Third-Generation Sequencing market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity…
世界の次世代シーケンシング市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Next-Generation Sequencing Market The global Next-Generation Sequencing market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, …
世界の次世代シーケンシング情報市場規模・現状・予測（2021年-2027年） Next-Generation Sequencing Informatics, also known as High-throughput sequencing, is marked by the ability to sequence one hundred thousand to one million DNA molecules in parallel, often with short readings. Market Analysis and Insights: Global Next-Generation Sequencing Informatics Market The glob…
世界の次世代シーケンシング（NGS）データ分析市場規模・現状・予測（2021年-2027年） North America is home to several well-established organizations of NGS data analysis. A significant number of NGS research projects are being carried out in Canadian universities, which in turn has resulted into huge demand for NGS data analysis, thereby affecting the revenue growth in the region. N…
世界の次世代シーケンシング（NGS）市場規模・現状・予測（2021年-2027年） NGS is a technology in which millions and billions of DNA strands can be sequenced through massive parallelization. This technique is also known as high throughput sequencing. The impact of the driving factors is expected to overcome the effect of restraints. Moreover, the utilization of cloud compu…